Cascinu,Stefano

Institution: Clinica di Oncologia Medica, Italy

Research Interests: Patients, Cancer, Treatment, Survival, Colorectal Cancer, Tumor, Carcinoma, Cell, Role, Chemotherapy, Tumors, Disease, Renal Cell Carcinoma, Endothelial Growth Factor, Growth, Vascular Endothelial Growth Factor, Prognosis, Therapeutic, Time, Epidermal Growth Factor

Publications

Information and abstracts for author publications
Published Date	Impact	Publication
12/13/2013	10.6	Cancer metastasis reviews Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.	Abstract
10/07/2008	6.4	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.	Abstract
11/23/2011	6.4	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.	Abstract
10/06/2010	6.4	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients.	Abstract
08/25/2010	6.1	Cancer treatment reviews Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.	Abstract
08/30/2010	5.4	International journal of cancer. Journal international du cancer Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.	Abstract
11/18/2013	5.4	International journal of cancer. Journal international du cancer Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.	Abstract
11/18/2013	5.4	International journal of cancer. Journal international du cancer Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.	Abstract
08/22/2008	5.3	Critical reviews in oncology/hematology Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review.	Abstract
06/24/2013	5.3	Critical reviews in oncology/hematology Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.	Abstract
05/10/2011	5	British journal of cancer Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.	Abstract
11/29/2012	5	British journal of cancer VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.	Abstract
02/07/2012	5	British journal of cancer Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.	Abstract
09/05/2013	5	British journal of cancer Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma.	Abstract
04/29/2013	4.3	Current cancer drug targets Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?	Abstract
04/20/2009	4.1	International journal of radiation oncology, biology, physics Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome.	Abstract
09/04/2013	4.1	PloS one Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.	Abstract
03/26/2012	4.1	PloS one The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management.	Abstract
11/12/2013	4.1	PloS one Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.	Abstract
10/03/2013	4	Pharmacogenomics Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.	Abstract
02/21/2011	4	Pharmacogenomics 5-Fluorouracil pharmacogenomics: still rocking after all these years?	Abstract
01/06/2011	3.9	The oncologist The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.	Abstract
10/17/2013	3.7	Cancer immunology, immunotherapy : CII Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.	Abstract
06/03/2010	3.7	Current opinion in molecular therapeutics Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.	Abstract
04/08/2013	3.5	Expert opinion on biological therapy Cetuximab: still an option in the treatment of pancreatic cancer?	Abstract
04/10/2012	3.5	Journal of translational medicine Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.	Abstract
08/06/2009	3.4	Lung cancer (Amsterdam, Netherlands) Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?	Abstract
04/06/2013	3.2	Journal of neuro-oncology Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.	Abstract
09/15/2009	3.2	Expert opinion on pharmacotherapy Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1.	Abstract
11/28/2013	3.2	Expert opinion on pharmacotherapy Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey.	Abstract
09/18/2009	3.2	Expert opinion on pharmacotherapy Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2.	Abstract
04/26/2013	3.2	Future oncology (London, England) Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.	Abstract
08/21/2010	3.1	Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.	Abstract
08/27/2009	3	BMC cancer Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.	Abstract
05/24/2013	2.9	Current protein & peptide science Essential role of Gli proteins in glioblastoma multiforme.	Abstract
04/28/2010	2.5	Current oncology reports Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy.	Abstract
12/15/2010	2.1	Journal of experimental & clinical cancer research : CR Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis.	Abstract